

Philip Owens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3090922/publications.pdf>

Version: 2024-02-01

43
papers

2,287
citations

257357

24
h-index

302012

39
g-index

43
all docs

43
docs citations

43
times ranked

4738
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Neoadjuvant endocrine therapy expands stromal populations that predict poor prognosis in estrogen receptor-positive breast cancer. <i>Molecular Carcinogenesis</i> , 2022, 61, 359-371. | 1.3 | 2 |
| 2 | Cover Image, Volume 61, Issue 3. <i>Molecular Carcinogenesis</i> , 2022, 61, . | 1.3 | 0 |
| 3 | miR-31 Displays Subtype Specificity in Lung Cancer. <i>Cancer Research</i> , 2021, 81, 1942-1953. | 0.4 | 11 |
| 4 | Adenosine/TGF β 2 axis in regulation of mammary fibroblast functions. <i>PLoS ONE</i> , 2021, 16, e0252424. | 1.1 | 9 |
| 5 | Abstract 114: Loss of BMPR1a in fibroblasts restricts breast cancer progression and alters the immune tumor microenvironment. , 2021, , . | | 1 |
| 6 | Mechanobiology of Bone Metastatic Cancer. <i>Current Osteoporosis Reports</i> , 2021, 19, 580-591. | 1.5 | 6 |
| 7 | Targeting the BMP Pathway in Prostate Cancer Induced Bone Disease. <i>Frontiers in Endocrinology</i> , 2021, 12, 769316. | 1.5 | 7 |
| 8 | Integrating the immune microenvironment of prostate cancer-induced bone disease. <i>Molecular Carcinogenesis</i> , 2020, 59, 822-829. | 1.3 | 9 |
| 9 | Loss of Myeloid BMPR1a Alters Differentiation and Reduces Mouse Prostate Cancer Growth. <i>Frontiers in Oncology</i> , 2020, 10, 357. | 1.3 | 11 |
| 10 | Myeloid Cell-derived TGF β 2 Signaling Regulates ECM Deposition in Mammary Carcinoma via Adenosine-Dependent Mechanisms. <i>Cancer Research</i> , 2020, 80, 2628-2638. | 0.4 | 28 |
| 11 | Distinct tumor microenvironments of lytic and blastic bone metastases in prostate cancer patients. , 2019, 7, 293. | | 45 |
| 12 | Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination. <i>Clinical Cancer Research</i> , 2019, 25, 3352-3365. | 3.2 | 18 |
| 13 | Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER + breast cancer. <i>FASEB Journal</i> , 2019, 33, 1644-1657. | 0.2 | 13 |
| 14 | Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer. <i>Journal of Experimental Medicine</i> , 2018, 215, 895-910. | 4.2 | 63 |
| 15 | TGF- β 2, Bone Morphogenetic Protein, and Activin Signaling and the Tumor Microenvironment. <i>Cold Spring Harbor Perspectives in Biology</i> , 2017, 9, a022285. | 2.3 | 47 |
| 16 | The Yin/Yan of CCL2: a minor role in neutrophil anti-tumor activity in vitro but a major role on the outgrowth of metastatic breast cancer lesions in the lung in vivo. <i>BMC Cancer</i> , 2017, 17, 88. | 1.1 | 29 |
| 17 | HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. <i>Clinical Cancer Research</i> , 2017, 23, 4323-4334. | 3.2 | 64 |
| 18 | Development of Aggressive Pancreatic Ductal Adenocarcinomas Depends on Granulocyte Colony Stimulating Factor Secretion in Carcinoma Cells. <i>Cancer Immunology Research</i> , 2017, 5, 718-729. | 1.6 | 41 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | ErbB3 drives mammary epithelial survival and differentiation during pregnancy and lactation. <i>Breast Cancer Research</i> , 2017, 19, 105. | 2.2 | 23 |
| 20 | TÎ²RIII Expression in Human Breast Cancer Stroma and the Role of Soluble TÎ²RIII in Breast Cancer Associated Fibroblasts. <i>Cancers</i> , 2016, 8, 100. | 1.7 | 9 |
| 21 | Emerging roles of the bone morphogenetic protein pathway in cancer: potential therapeutic target for kinase inhibition. <i>Biochemical Society Transactions</i> , 2016, 44, 1117-1134. | 1.6 | 40 |
| 22 | The Bone Microenvironment: a Fertile Soil for Tumor Growth. <i>Current Osteoporosis Reports</i> , 2016, 14, 151-158. | 1.5 | 52 |
| 23 | Bone morphogenetic protein signaling promotes tumorigenesis in a murine model of high-grade glioma. <i>Neuro-Oncology</i> , 2016, 18, 928-938. | 0.6 | 27 |
| 24 | Deletion of the BMP receptor BMPR1a impairs mammary tumor formation and metastasis. <i>Oncotarget</i> , 2015, 6, 22890-22904. | 0.8 | 37 |
| 25 | Genomic Analysis of the BMP Family in Glioblastomas. <i>Translational Oncogenomics</i> , 2015, 7, 1-9. | 1.7 | 12 |
| 26 | BMPR2 loss in fibroblasts promotes mammary carcinoma metastasis via increased inflammation. <i>Molecular Oncology</i> , 2015, 9, 179-191. | 2.1 | 30 |
| 27 | Small molecule inhibitor of the bone morphogenetic protein pathway DMH1 reduces ovarian cancer cell growth. <i>Cancer Letters</i> , 2015, 368, 79-87. | 3.2 | 32 |
| 28 | TGFÎ² Signaling in Myeloid Cells Regulates Mammary Carcinoma Cell Invasion through Fibroblast Interactions. <i>PLoS ONE</i> , 2015, 10, e0117908. | 1.1 | 17 |
| 29 | Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets. <i>Cancer Discovery</i> , 2014, 4, 232-245. | 7.7 | 413 |
| 30 | Attenuated transforming growth factor beta signaling promotes metastasis in a model of HER2 mammary carcinogenesis. <i>Breast Cancer Research</i> , 2014, 16, 425. | 2.2 | 20 |
| 31 | Role of TGF-Î² Signaling in Generation of CD39+CD73+ Myeloid Cells in Tumors. <i>Journal of Immunology</i> , 2014, 193, 3155-3164. | 0.4 | 101 |
| 32 | Stromally Derived Lysyl Oxidase Promotes Metastasis of Transforming Growth Factor-Î²-Deficient Mouse Mammary Carcinomas. <i>Cancer Research</i> , 2013, 73, 5336-5346. | 0.4 | 164 |
| 33 | Bone Morphogenetic Proteins Stimulate Mammary Fibroblasts to Promote Mammary Carcinoma Cell Invasion. <i>PLoS ONE</i> , 2013, 8, e67533. | 1.1 | 42 |
| 34 | Disruption of bone morphogenetic protein receptor 2 (BMPR2) in mammary tumors promotes metastases through cell autonomous and paracrine mediators. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 2814-2819. | 3.3 | 81 |
| 35 | Deletion of TGF-Î² signaling in myeloid cells enhances their anti-tumorigenic properties. <i>Journal of Leukocyte Biology</i> , 2012, 92, 641-651. | 1.5 | 63 |
| 36 | TGF-Î² Receptor II Loss Promotes Mammary Carcinoma Progression by Th17-Dependent Mechanisms. <i>Cancer Discovery</i> , 2011, 1, 430-441. | 7.7 | 116 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Epidermal Smad4 Deletion Results in Aberrant Wound Healing. American Journal of Pathology, 2010, 176, 122-133. | 1.9 | 44 |
| 38 | The Role of Smads in Skin Development. Journal of Investigative Dermatology, 2008, 128, 783-790. | 0.3 | 56 |
| 39 | Smad4-dependent desmoglein-4 expression contributes to hair follicle integrity. Developmental Biology, 2008, 322, 156-166. | 0.9 | 33 |
| 40 | IKK β is a critical coregulator of a Smad4-independent TGF β 2-Smad2/3 signaling pathway that controls keratinocyte differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 2487-2492. | 3.3 | 138 |
| 41 | Smad7-Induced β -Catenin Degradation Alters Epidermal Appendage Development. Developmental Cell, 2006, 11, 301-312. | 3.1 | 144 |
| 42 | Role of TGF β 2-Mediated Inflammation in Cutaneous Wound Healing. Journal of Investigative Dermatology Symposium Proceedings, 2006, 11, 112-117. | 0.8 | 189 |
| 43 | Constitutive TGF β 1 Overexpression in Mouse Keratinocytes Delays Cutaneous Wound Healing. Wound Repair and Regeneration, 2005, 13, A4-A27. | 1.5 | 0 |